NCT06666166View on ClinicalTrials.gov

SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

July 31, 2028

Study Completion Date

December 31, 2028

Conditions
Advanced Gastric CarcinomaAdvanced Gastroesophageal Junction AdenocarcinomaAdvanced Colorectal Cancer
Interventions
DRUG

SHR-A1811 & Apartinib

SHR-A1811 injection will be administered by intravenous infusion. And apatinib will be administered orally.

Trial Locations (1)

Unknown

The First Hospital of China Medical University, Shenyang

All Listed Sponsors
collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

Yunpeng Liu

OTHER